Neuralink, a neurotechnology company founded by Elon Musk, has earned $650 million in Series E funding from several key investors.
The company will use the funding to “accelerate our efforts to expand patient access and innovate future devices that deepen the connection between biological and artificial intelligence,” according to a June 2 news release.
Currently, Neuralink is carrying out four clinical trials for its brain-computer interface, a system that is implanted in a patient’s brain to restore some functions for patients with paralysis. So far, the device has been implanted in five patients.
It completed its last funding round in August 2023.
Neuralink, whose technology was implanted into a human for the first time in January 2024, now has several competitors on the market, including Paradromics, Synchron and Precision Neuroscience.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
